Leveraging a flexible and efficient Rapid Development Framework™ to accelerate development and manufacturing of cell and gene therapies
Watch On-Demand →Accelerate the development and manufacturing of cell and gene therapies
The translation of cell and gene therapies (CGTs) is often complicated by the challenges associated with progressing innovative R&D processes to standardized and robust manufacturing methods. Early identification and mitigation of potential risks through consistent processes and robust qualifiable assays is essential to successful commercialization of these novel products. While traditional platform processes for CGTs offer accelerated production timelines, they may involve restrictive protocols that can box users into a suboptimal system.
As an alternative to this standard approach, Thermo Fisher Scientific has developed the Rapid Development FrameworkTM to streamline the complexity of regenerative medicine and immunotherapy workflows. Developed with 20+ years of advanced therapy industry experience and expertise, these frameworks for processes and analytics are designed to expedite development and manufacturing while remaining adaptable to the unique needs of each product.
Watch our webinar to learn more, including:
- Examples of specific Rapid Development Frameworks for viral vector, CAR-T, and iPSC workflows and associated analytics
- Additional pathways to accelerate development and manufacturing timelines leveraging CDMO capabilities
- Advantages of this approach in promoting consistency, reducing failure risks, and ultimately enhancing product quality and patient safety
- Examples of Rapid Development Frameworks in practice with associated time and cost savings
Complete the form to watch now
Watch On-Demand →Meet the Speakers

Mindy Sadik, PhD
Director, Cell Therapy Sciences at Thermo Fisher Scientific

TJ Chancellor, PhD
Senior Manager, Technical Program Design at Thermo Fisher Scientific